{
    "clinical_study": {
        "@rank": "72107", 
        "arm_group": {
            "arm_group_label": "Carfilzomib", 
            "arm_group_type": "Experimental", 
            "description": "All eligible subjects will receive the study intervention of Carfilzomib.  Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment."
        }, 
        "brief_summary": {
            "textblock": "This is a dose finding study to evaluate the safety and determine the maximum tolerated dose\n      of carfilzomib in patients with previously treated systemic light-chain amyloidosis.  The\n      study will also explore the efficacy of carfilzomib in both proteasome inhibitor-naive and\n      proteasome inhibitor-exposed patients including hematologic response, organ response,\n      progression free survival, and time to next therapy."
        }, 
        "brief_title": "A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Amyloidosis", 
            "Systemic Light Chain Amyloidosis"
        ], 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females \u2265 18 years of age\n\n          -  Histologically-proven AL amyloidosis, confirmed by positive Congo red stain with\n             green birefringence on polarized light microscopy with evidence of measurable clonal\n             disease that requires active treatment as defined below:\n\n          -  Patients must have clonal disease measureable by serum free light chain (FreeliteTM)\n             assay:\n\n               -  For the dose-escalation cohort: this is defined as having any elevation in the\n                  amyloidogenic (i.e. clonal) light chain with an abnormal free kappa:lambda ratio\n\n               -  For the dose expansion cohorts: in addition to the above, there must be a\n                  difference between the amyloidogenic (i.e. clonal) and non-amyloidogenic light\n                  chain (dFLC) of at least 50mg/L (5mg/dL)\n\n          -  Relapsed (progressed after prior response) or refractory (failed to achieve at least\n             a partial response) to at least one prior therapy for amyloidosis.\n\n               -  Patients that received an autologous stem cell transplant must be at least 3\n                  months post-transplant and recovered from acute transplant-related toxicities.\n\n               -  Patients that were unable to tolerate at least 1 cycle of an alkylating agent\n                  plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior\n                  regimen because of severe adverse events (e.g. hypersensitivity reaction) may be\n                  considered after discussion with the study PI/Medical Monitor.\n\n          -  Objective, measureable, symptomatic organ involvement, defined as one or more of the\n             following:\n\n               -  Kidney: albuminuria \u2265 500 mg/day in a 24-hour urine specimen\n\n               -  Heart: presence of mean left ventricular wall thickness on echocardiogram\n                  greater than 12 mm in the absence of hypertension or valvular heart disease, or\n                  unexplained low voltage (< 0.5 mV) on ECG, or NT-proBNP > 332 ng/L in the\n                  absence of impaired renal function [estimated glomerular filtration rate (eGFR)\n                  < 45 mL/min]\n\n               -  Liver: hepatomegaly on physical exam with elevated alkaline phosphatase > 1.5 x\n                  ULN\n\n               -  GI Tract: biopsy showing amyloid deposition along with symptoms such as GI\n                  bleeding or persistent diarrhea (> 4 loose stools/day) Autonomic or Peripheral\n                  Nervous System: defined as orthostasis, symptoms of nausea or dysgeusia,\n                  recurrent diarrhea or constipation, abnormal sensory and/or motor findings on\n                  neurologic exam, or gastric atony by gastric emptying scan\n\n               -  Note: Skin, lymph node, or soft tissue involvement; carpal tunnel syndrome; or\n                  bone marrow amyloid as the sole clinical manifestations of amyloidosis are not\n                  sufficient for inclusion.\n\n          -  Amyloid cardiac biomarker stage I or II disease Staging defined by NT-proBNP and\n             troponin T cut-offs of < 332 pg/mL and <0.035 ng/mL, respectively, as thresholds:\n             Stage I, both under threshold; and Stage II, either troponin or NT-proBNP (but not\n             both) over threshold.  If troponin T is not available at local institution, troponin\n             I may be used, but threshold is <0.1 ng/mL.23\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n          -  Clinical laboratory values as specified within 14 days of treatment:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.0 x 109/L\n\n               -  Hemoglobin \u22658 g/dL [transfusion permitted]\n\n               -  Platelet count \u226575.0 x 109/L\n\n               -  Total bilirubin \u2264 2 x Upper Limit of Normal (ULN)\n\n               -  Alkaline phosphatase \u2264 5 x ULN\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3.5 x ULN\n\n               -  CrCl \u2265 30 mL/min as measured by 24-hour urine\n\n               -  Screening ANC should be independent of granulocyte-and granulocyte/macrophage\n                  colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of\n                  pegylated G-CSF for at least 2 weeks\n\n               -  Screening platelet count should be independent of platelet transfusions for at\n                  least 2 weeks\n\n          -  Written informed consent in accordance with federal, local, and institutional\n             guidelines\n\n          -  Females of childbearing potential must agree to ongoing pregnancy testing and to\n             practice contraception or abstain from heterosexual intercourse\n\n          -  Male patients must agree to practice contraception or to abstain from heterosexual\n             intercourse\n\n          -  Male patients must agree not to donate semen or sperm\n\n          -  Life expectancy of \u2265 3 months\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females\n\n          -  Major surgery within 21 days prior to first dose\n\n          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals\n             within 14 days prior to first dose\n\n          -  Treatment with an experimental drug within 28 days of first dose\n\n          -  Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection\n\n          -  Bone marrow plasma cells \u2265 30% or clinical manifestations of multiple myeloma, such\n             as hypercalcemia or lytic bone lesions\n\n          -  Cardiac exclusions:\n\n               -  Left ventricular ejection fraction (LVEF) < 40%\n\n               -  Amyloid cardiac biomarker stage III disease, defined as both NT-proBNP \u2265 332\n                  pg/mL and troponin T \u2265 0.035 ng/mL.  If troponin T is not available at local\n                  institution, troponin I may be used, but cut-off is \u2265 0.1 ng/mL\n\n               -  New York Heart Association (NYHA) classification III or IV heart failure (see\n                  Appendix G) despite medical management\n\n               -  Unstable angina or myocardial infarction within 6 months prior to first dose\n\n               -  Grade 2 or 3 atrioventricular (AV) block (Mobitz type I is permitted) or sick\n                  sinus syndrome, unless subject has a pacemaker\n\n               -  Known history of sustained (> 30 second) ventricular tachycardia or cardiac\n                  syncope.  Known history of recurrent non-sustained ventricular tachycardia (> 3\n                  beats) despite anti-arrhythmic therapy\n\n               -  Supine systolic blood pressure < 90 mm Hg, or symptomatic orthostatic\n                  hypotension, or a decrease in systolic blood pressure upon standing of > 20 mm\n                  Hg despite medical management (e.g. midodrine, fludrocortisones)\n\n          -  Significant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14\n             days prior to first dose\n\n          -  Severe diarrhea (\u2265 grade 3) not controllable with medication or that requires total\n             parenteral nutrition\n\n          -  History of bleeding diathesis, known factor X deficiency (level < 20%), or\n             requirement for therapeutic anticoagulation with warfarin\n\n          -  Known allergies to carfilzomib or Captisol\u00ae (a cyclodextrin derivative used to\n             solubilize carfilzomib)\n\n          -  Presence of other active malignancy with the exception of non-melanoma skin cancer,\n             cervical cancer, treated early-stage prostate cancer provided that prostate-specific\n             antigen is within normal limits, or any completely resected carcinoma in situ\n\n          -  Serious psychiatric or medical conditions that could interfere with treatment\n\n          -  Contraindication to any of the required concomitant drugs, including antiviral (e.g.\n             Valacyclovir)\n\n          -  Patients in whom the required program of oral and IV fluid hydration is\n             contraindicated, e.g. due to severe pre-existing pulmonary, cardiac, or renal\n             impairment\n\n          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring\n             paracentesis within 14 days prior to first dose."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789242", 
            "org_study_id": "AMyC 11MM02", 
            "secondary_id": "IST-CAR-545"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carfilzomib", 
                "description": "IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PR-171", 
                    "Kyprolis"
                ]
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Decadron"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Lucinda Pena", 
                    "phone": "626-256-4673", 
                    "phone_ext": "64816"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Michael Rosenzweig, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vani@stanford.edu", 
                    "last_name": "Vani Jain", 
                    "phone": "650-725-5449"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Michaela Liedtke, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alaina.r.mitchell@emory.edu", 
                    "last_name": "Alaina Mitchell", 
                    "phone": "404-778-5747"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Winship Cancer Institute of Emory University"
                }, 
                "investigator": {
                    "last_name": "Jonathan Kaufman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "juliana.merhaut@bmc.org", 
                    "last_name": "Juliana Merhaut", 
                    "phone": "617-638-8280"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Vaishali Sanchorawala, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kbarga@hackensackUMC.org", 
                    "last_name": "Kevin Barga, RN", 
                    "phone": "551-996-8017"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center at Hackensack University Medical Center"
                }, 
                "investigator": {
                    "last_name": "David Vesole, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ts2257@columbia.edu", 
                    "last_name": "Tasha Smith", 
                    "phone": "212-305-2460"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University"
                }, 
                "investigator": {
                    "last_name": "Suzanne Lentzsch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ciccolel@mskcc.org", 
                    "last_name": "Lauren Ciccolella", 
                    "phone": "646-449-1468"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Heather J Landau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberly.bartlett@duke.edu", 
                    "last_name": "Kimberly Oates, RN, OCN", 
                    "phone": "919-668-6524"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Cristina Gasparetto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bedford2@ohsu.edu", 
                    "last_name": "Amy Bedford", 
                    "phone": "503-494-6171"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Sciences University"
                }, 
                "investigator": {
                    "last_name": "Emma Scott, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Scott.Weber@uphs.upenn.edu", 
                    "last_name": "Scott Weber", 
                    "phone": "215-662-8790"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Abramson Cancer Center at the University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Adam Cohen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis", 
        "other_outcome": [
            {
                "description": "Impact on hematologic response and toxicity of adding dexamethasone to carfilzomib in patients with suboptimal hematologic responses (defined as <VGPR after 4 cycles)", 
                "measure": "Impact on hematologic response and toxicity of adding dexamethasone", 
                "safety_issue": "Yes", 
                "time_frame": "Every 28 days throughout treatment after dexamethasone is added (estimated at 4 months per patient)"
            }, 
            {
                "description": "Evaluate potential biomarkers of carfilzomib sensitivity in baseline purified bone marrow plasma cells, including proteasomal capacity and in vitro sensitivity to proteasome inhibition.", 
                "measure": "Biomarkers of carfilzomib sensitivity", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "To explore the prognostic significance of cyclin D1 expression in purified bone marrow plasma cells in patients with previously treated AL amyloidosis", 
                "measure": "Prognostic significance of cycle D1 expression", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "AMyC; Univ of Penn Perelman Center for Advanced Medicine", 
                "last_name": "Adam Cohen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academic Myeloma Consortium", 
                "last_name": "Brian GM Durie, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AMyC, Tufts University", 
                "last_name": "Raymond Comenzo, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment", 
            "measure": "Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout treatment, estimated at 8 months per patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hematologic Response Rates (PR, VGPR, and CR", 
                "measure": "Hematologic Response", 
                "safety_issue": "No", 
                "time_frame": "Every 28 days while on treatment (estimated at 8 months per patient)"
            }, 
            {
                "description": "Organ response rates by standard criteria", 
                "measure": "Organ Response", 
                "safety_issue": "No", 
                "time_frame": "Every 112 days while on treatment (estimated at 8 months per patient)"
            }, 
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "throughout study and follow up (every 2-3 months for 2 years"
            }, 
            {
                "measure": "Time to next therapy", 
                "safety_issue": "No", 
                "time_frame": "throughout follow up (every 2-3 months for 2 years)"
            }
        ], 
        "source": "Academic Myeloma Consortium", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Onyx Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "CORE Science Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Criterium Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Academic Myeloma Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}